In a big boost to India’s emerging deep-tech and biotech ecosystem, Helex, a next-generation biotechnology startup operating out of Hyderabad and the United States, has secured US$3.5 million in a seed funding round. pi Ventures led this round along with participation from Bluehill Capital, SOSV, and several other global investors. The fresh capital marks an important milestone for India’s biotech ecosystem, reinforcing investor confidence in cutting-edge research and AI-driven life sciences.
Pioneering AI in Molecular Biology
Co-founded by Dr. Arjun Mahadevan and Dr. Sneha Rao, Helex works at applying AI and advanced computational biology to build precision diagnostics and therapeutic solutions. The company’s proprietary platform integrates genomics, machine learning, and molecular modeling to accelerate drug discovery and speed up disease detection.
Helex’s vision is to change the way genetic data are analyzed and used in healthcare. By automating the discovery process, the company aims to significantly cut the time and cost of R&D-the area considered one of the most significant bottlenecks in the biotech sector.
Dr. Mahadevan, CEO of Helex, thus commented:
“Our mission is to bridge the gap between biology and computation. Having AI at the heart of our platform will enable us to bring life-saving therapies and diagnostics to market much faster than conventional methods allow.”
Investor Confidence in Deep-Tech Biotech
Lead investor pi Ventures—one of the earliest deep-tech venture funds from India—cited the potential of Helex to disrupt molecular research and drug design. The fund, as it claims, has been an investor in a string of high-science startups at the intersection of AI, data, and core science.
Manish Singhal, Founding Partner at pi Ventures, said,
“Helex represents the next wave of innovation in biotech. By combining India’s scientific talent with global-grade computational tools, they’re positioned to redefine what’s possible in diagnostics and therapeutics.
Supporting investors, such as Bluehill Capital and SOSV, are also showing a growing interest in Indian biotech ventures, envisaging them as high-impact opportunities within the global health-tech ecosystem. It underlines the international appetite for Indian innovation, especially startups operating in cross-border collaboration models.
Use of Funds and Future Roadmap
Helex intends to use the $3.5 million in seed funding to expand research capabilities, build advanced data infrastructure, and scale up its AI-driven discovery platform. Most of the investment will be channelized towards recruiting top bioinformaticians, data scientists, and molecular biologists for its hybrid team based out of India and the US.
The company is also setting up a state-of-the-art genomics lab in Hyderabad that will act as a central hub for computational and experimental synergy. The lab will work on the creation of AI models with better predictive analytics for protein interactions, disease markers, and therapeutic targets.
In the medium term, it would seek to collaborate with international pharmaceutical companies and research institutes for the co-development of new therapies and diagnostics. Because of the versatility of the platform, this will have wide-ranging applications across fields like oncology, immunology, and rare genetic disorders.
Biotech Gains Increasing Momentum in India
Helex gets funded at a point when both innovation and investor interest in India’s biotech is at an all-time high. According to data by Invest India, the biotech industry, which is expected to grow to $300 billion by 2030, is driven by increasing R&D, government incentives, and rising health-tech integration.
Companies like Helex are at the forefront of this transformation: marrying computational power with biological insight. With AI now a cornerstone of modern biotech, the sector will move toward quicker discovery cycles, personalized medicine, and predictive healthcare.
Furthermore, Indian biotech ventures are increasingly being seen by global venture funds as cost-efficient but rich in innovation. This unlikely marriage of Indian scientists and global capital has created a new tide of startups ready to compete in the world.
Bridging Science and Scalability
What sets Helex apart is not just the depth of its science but the vision for democratizing access to precision medicine. Building scalable AI models, the startup hopes to equip smaller labs, hospitals, and pharmaceutical firms with predictive insights previously available only to large research organizations.
Co-founder Dr. Sneha Rao said in a statement,
“Science shouldn’t just remain in the labs; it should reach the patients faster. Our goal is to make advanced biotechnology accessible, affordable, and of impactful relevance to global healthcare.
A Glimpse into the Future The successful seed round by Helex signals a growing convergence of biotechnology, AI, and data-driven medicine. As it prepares for global expansion, the startup now stands as a beacon of India’s rising influence in deep-tech and life sciences innovation. By coupling scientific rigor with technological disruption, Helex isn’t just raising capital but redefining how the world approaches health research in the 21st century.
